{
    "medicine_id": "db2495615a9d0f5c29cbd31e1074de70965d1f01",
    "platform_id": "DB00053",
    "metadata": {
        "name": "Cerezyme 40 U 1mL Injection powder lyophilized for solution",
        "composition": "40 U 1mL Imiglucerase",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of Gaucher s disease deficiency in glucocerebrosidase",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Gaucher disease is characterized by a functional deficiency in Beta glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells Gaucher cells are typically found in liver spleen and bone marrow This can lead to an enlarged spleen and liver hepatosplenomegaly Secondary hematologic sequelae include severe anemia and thrombocytopenia Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia reduced spleen and liver size and decreased cachexia",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}